The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LTUS | -25.53% | -76.67% | -25.23% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +413% |
Lotus Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products in the People's Republic of China. Its products are prescription medicines, including Valsartan, used to reduce hypertension and high blood pressure, Brimonidine Tartrate, used to constrict adrenaline receptors, Levofloxacin Lactate, an intravenous anti-bacterial drug, and Nicergoline, an anti-dementia drug. The firm also distributes products on behalf of third-party pharmaceutical manufacturers directly through its distribution network. The company was founded by Zhongyi Liu in 1996 and is headquartered in North Port, FL.
No news articles found for Lotus Pharmaceuticals.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $183.60K | 69.2% |
| Market Cap / Employee | $14.12K | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | -$6.40K | -156.0% |
| EBITDA | -$6.40K | -156.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.45K | 245.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $279.58K | 126.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3995.50% | 4400.1% |
| Return On Invested Capital | 20.26% | -20.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.38K | 64.2% |
| Operating Free Cash Flow | -$1.38K | 64.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -72.50 | -120.00 | 0.00 | -66.00 | -32.31% |
| Price to Tangible Book Value | -65.54 | -131.70 | 0.00 | -64.23 | -28.65% |
| Price to Free Cash Flow TTM | 140.69 | 106.49 | 143.53 | - | |
| Enterprise Value to EBITDA | -1796.03 | -7408.96 | - | -2770.61 | -34.85% |
| Free Cash Flow Yield | 0.7% | 0.9% | 0.7% | - | |
| Total Debt | $124.93K | $0.00K | $274.56K | $279.58K | 126.50% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
